Description: Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.
Home Page: www.medigene.com
Lochhamer Strasse 11
Munich,
82152
Germany
Phone:
49 89 2000 330
Officers
| Name | Title |
|---|---|
| Dr. Selwyn Ho MB BS, MBBS | CEO & Chairman of Executive Management Board |
| Dr. Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development |
| Dr. Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board |
| Dr. Birger Kohlert | Chief Financial Officer |
| Pamela Keck | Vice President of Investor Relations & Corporate Communications |
| Dr. Kirsty Crame M.D. | VP and Head of Clinical Research & Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8379 |
| Price-to-Sales TTM: | 5.1263 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 87 |